References | Geographic region (study years) | Patients | Arms or cohorts | Patients with ED visits, # (%) | # of ED visits | Mean annual ED # visits/patient |
---|---|---|---|---|---|---|
Polisena et al. [17] | Calgary (1998–2009) | ≥60 years (mean age) | Telephone support | 40.6 % of patients | 0.1 visits | |
Usual care | 63.15 % of patients | 0.4 visits | ||||
Labrecque et al. [29] | Montreal (2004) | 40–75 years, stable COPD | Self-management education (n = 57) | Pre-index 1.1 visits Post-index 0.2 visits | ||
Usual care (n = 45) | Pre-index 0.4 visits Post-index 0.4 visits | |||||
Canada (1 year study) | Diagnosed/undiagnosed COPD patients | All patients (n = 401) | 70 patients (17.5 %) | 151 visits | 0.38 visits | |
Moullec et al. [28] | Montreal (2004–2006) | Montreal hospital patients | Integrated care (n = 96) | Prior year 27 (28.1 %), Post-Index 28 (29.2 %) | Pre and Post-Index 0.5 visits | |
Usual care (n = 93) | Prior year 27 (29.0 %), Post-Index 26 (28.0 %) | Pre and Post-Index 0.5 visits | ||||
Bischoff et al. [39] | COPD patients, ≥40 years | All patients (n = 119) | Preceding year 0.65 visits | |||
Rowe et al. [34] | US, Canada | ≥55 year, stable COPD | Canadian patients (n = 63) | Previous year 1.0 visits | ||
Tsai et al. [45] | US, Canada | ≥55 year, stable COPD | Underweight (BMI <18.5, n = 50) | Previous year 2.0 visits | ||
Normal weight (BMI 18.5–24.9, n = 148) | Previous year 1.0 visits | |||||
Overweight (BMI 25–29.9, n = 105) | Previous year 1.0 visits | |||||
Obese (BMI ≥ 30, n = 92) | Previous year 1.0 visits | |||||
Sin et al. [38] | (1992–1997) | age ≥65 years, discharged diagnosis of COPD | No inhaled corticosteroid (n = 11,139) | Preceding year 1.2 visits | ||
Inhaled corticosteroid (n = 11,481) | Preceding year 1.6 visits | |||||
Johnston et al. [32] | Hamilton, Ontario (Dec 2006–Jan 2007) | ≥40 year, COPD of mixed severity | GOLD stratum 0 (n = 39) | Previous year 1.6 visits | ||
GOLD stratum 1 and 2 (n = 31) | Previous year 1.4 visits | |||||
GOLD stratum 3 and 4 (n = 44) | Previous year 1.8 visits | |||||
Wang et al. [35] | Montreal (2 year study) | ≥40 years, Moderate-severe COPD hospitalized | All Patients (n = 282) | 54 patients (19.1 %) | 99 visits | 1.82 visits |
Alberta (1999–2005) | ≥55 years | All patients (38,638) | 38,638 patients | 85,330 visits | 2.2 visits | |
Golmohammadi et al. [36] | Edmonton (2000–2002) | >45 years | Rehab program: DSS-S1 (n = 31) | Pre 42.1 visits/100 pt-years Post 13.6 visits/100 pt-years | ||
Rehab program: DSS-S2A (n = 78) | Pre 57.0 visits/100 pt-years Post 44.8 visits/100 pt-years | |||||
Rehab program: DSS-S2B (n = 51) | Pre 29.5 visits/100 pt-years Post 16.3 visits/100 pt-years | |||||
Rehab program: DSS-S3 (n = 41) | Pre 41.0 visits/100 pt-years Post 54.4 visits/100 pt-years | |||||
Stephenson et al. [40] | Ontario (2003–2010) | >66 years, Concomitant dementia and COPD | ChEI users (n = 7166) | Baseline 538 (7.5 %) | ||
ChEI non-users (n = 7166) | Baseline 517 (7.2 %) | |||||
Blais et al. [41] | Quebec (Feb 2003–Jan 2007) | ≥40 years | Budesonide/formoterol (n = 1131) | 10.3 % of patients | 182 visits | |
Propionate/salmeterol (n = 1131) | 13.1 % of patients | 256 visits | ||||
Gershon et al. [42] | Ontario (2003–2007) | ≥66 years | Long-acting anticholinergic (n = 28,563) | 12.2 % of patients | ||
Long-acting beta-agonist (n = 17,840) | 11.7 % of patients | |||||
FitzGerald et al. [43] | Canada (1 year study) | ≥40 year | All patients (n = 609), all exacerbation (n = 691) | 193 visits | ||
Patients with exacerbations (n = 278) | 111 patients (39.9 %) | |||||
Sedeno et al. [21] | COPD patients | Usual care (n = 81) | 54.4 % patients | |||
Self-management group (n = 85) | 29.9 % patients | |||||
Bourbeau et al. [44] | Advanced COPD, ≥1 hospitalization for exacerbation in last year | Usual care (n = 95) | 63.2 % patients | |||
Self-management care (n = 96) | 40.6 % patients | |||||
Mittmann et al. [3] | Canada | Moderate and severe COPD exacerbations | All patients (n = 609), all exacerbation (790 exacerbations) | 245 visits | ||
Moderate exacerbation (639 exacerbations) | 105 visits | |||||
Severe exacerbation (151 exacerbations) | 140 visits | |||||
Beauchesne et al. [77] | (1995–2004) | COPD patients | Home management program (n = 152) | 29 visits | ||
Dormuth et al. [60] | British Columbia | ≥45 years, 2.5-year period after public coverage | Predicted use | 6658 visits | ||
Observed use | 7434 visits |